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Abstract
Background & Aims: Controlled attenuation parameter (CAP) can measure hepatic steatosis. However, factors affecting its
accuracy have not been described yet. This study investigated predictors of discordance between liver biopsy (LB) and CAP.
Methods: A total of 161 consecutive patients with chronic liver disease who underwent LB and CAP were enrolled
prospectively. Histological steatosis was graded as S0 (,5%), S1 (5–33%), S2 (34–66%), and S3 (.66% of hepatocytes).
Cutoff CAP values were calculated from our cohort (250, 301, and 325 dB/m for$S1,$S2, and S3). Discordance was defined
as a discrepancy of at least two steatosis stages between LB and CAP.
Results: The median age (102 males and 59 females) was 49 years. Repartition of histological steatosis was as follows; S0
26.1% (n = 42), S1 49.7% (n = 80), S2 20.5% (n = 33), and S3 3.7% (n = 6). In multivariate linear regression analysis, CAP value
was independently associated with steatosis grade along with body mass index (BMI) and interquartile range/median of
CAP value (IQR/MCAP) (all P,0.05). Discordance was identified in 13 (8.1%) patients. In multivariate analysis, histological S3
(odd ratio [OR], 9.573; 95% confidence interval [CI], 1.207–75.931; P= 0.033) and CAP value (OR, 1.020; 95% CI, 1.006–1.034;
P= 0.006) were significantly associated with discordance, when adjusting for BMI, IQR/MCAP, and necroinflammation,
reflected by histological activity or ALT level.
Conclusions: Patients with high grade steatosis or high CAP values have a higher risk of discordance between LB and CAP.
Further studies are needed to improve the accuracy of CAP interpretation, especially in patients with higher CAP values.
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Introduction
Currently, the clinical implications of hepatic steatosis are
gaining more attention not only in Western countries, but also in
Asian countries with a westernized lifestyle such as Japan, China,
and Korea. [1,2] Indeed, the incidence of non-alcoholic fatty liver
disease (NAFLD), the most common condition of steatosis, is
increasing worldwide and it is now the most common cause of
abnormal liver function tests and chronic liver disease (CLD) in
both developed and developing countries. [3].
Severe forms of NAFLD can cause serious liver-related
complications such as liver failure and hepatocellular carcinoma.
[4,5] Furthermore, fatty burden can negatively influence the
prognosis of patients with CLD, as reported by recent studies
revealing that coexistent steatosis in chronic hepatitis C is
associated with fibrosis progression and decreased treatment
response, and that steatosis may lead to a poor postoperative
outcome such as a graft failure after liver transplantation or high
mortality after hepatectomy. [6–9] Moreover, these studies also
suggested that even low burden of hepatic steatosis could affect
treatment outcome or prognosis. Thus, an accurate diagnosis and
objective estimation of hepatic steatosis is important for clinical
decision-making and estimating the prognosis.
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To date, the gold standard for diagnosing and assessing the
severity of hepatic steatosis has been liver biopsy (LB). [10]
However, LB is an invasive and costly procedure with potential
limitations such as sampling error and unsatisfactory reproduc-
ibility. [11,12] Moreover, LB is difficult to repeat and it allows only
semiquantitative grading of steatosis. Although several non-
invasive methods such as ultrasonography, computed tomography
(CT), and magnetic resonance imaging (MRI) have been
investigated for this purpose, their clinical use is limited by high
cost, restrictive availability, operator dependence, and poor
sensitivity. [13,14].
Recently, interest has shifted towards controlled attenuation
parameter (CAP), which is based on the properties of ultrasonic
signals acquired by transient elastography (TE). [15] Previous
studies have demonstrated that CAP can be performed rapidly,
and painlessly with high patient acceptance and that it can
accurately grade the severity of steatosis in patients with CLDs.
[15–18] However, in contrast to a situation that several
confounding factors which determines the accuracy of liver
stiffness (LS) values such as interquartile range/median value
(IQR/M) or necroinflammatory activity have been identified,
factors that affect the accuracy of CAP in assessing hepatic
steatosis have not yet been identified. [19–22] Here, this study
investigated factors which can influence the diagnostic accuracy of
CAP for estimating the severity of hepatic steatosis.
Patients and Methods
Patients
Between November 2011 and August 2013, patients with CLD
of any etiology who were scheduled to undergo LB and CAP were
recruited for this prospective study at Severance Hospital, Yonsei
University College of Medicine, Seoul, Korea. The indications of
LB were (i) assessing the degree of inflammatory activity and the
extent of liver fibrosis in patients with viral hepatitis B and C, and
(ii) establish the cause of the liver disease in patients without viral
hepatitis. Exclusion criteria were as follows; (1) TE measurement
failure (no valid shot); (2) unreliable LS measurement; (3) non-
interpretable biopsies including insufficient specimen size ,
10 mm in length. Written informed consent was obtained from
all patients before enrollment. The study protocol was consistent
with the ethical guidelines of the 1975 Declaration of Helsinki.
Written informed consent was obtained from each participant.
This study was approved by the Ethics Committee/independent
institutional review board of Severance Hospital, Yonsei Univer-
sity College of Medicine, Seoul, Korea. The cohort of this study
included subjects recruited in our previous study [23] and we
enrolled additional subjects in the currnet study.
Measurement of Liver Stiffness and Controlled
Attenuation Parameter
All patients underwent TE using the Fibroscan M probe on the
same day as LB after fasting for at least 8 hour. [24] TE was
performed on the right lobe of the liver through the intercostal
spaces with the patient lying in the dorsal decubitus position with
the right arm in maximal abduction. Only one experienced
technician blind to the patients’ clinical data, was allowed to
perform TE. The principles of CAP measurement have been
described previously. [15] Briefly, the CAP measures ultrasonic
attenuations at 3.5 MHz using signals acquired by TE.
TE results were expressed as kilopascals (kPa) for LS and dB/m
for CAP. The interquartile range (IQR) was defined as an index of
the intrinsic variability of LS and CAP values corresponding to the
interval of LS and CAP results containing 50% of the valid
measurements between the 25th and 75th percentiles. The median
value of the successful measurements was selected as representative
of LS and CAP values for a given patient. As an indicator of
variability, the ratio of the IQR of LS and CAP values to the
median (IQR/M and IQR/MCAP, respectively) was calculated.
At the same time, hepatic steatosis was assessed using CAP
value, only when LS measurement was valid for the same signals,
ensuring that the liver ultrasonic attenuation was obtained
simultaneously from the same volume of liver parenchyma as LS
measurement. In this study, only TE measurement with at least 10
valid shots, and a success rate of at least 60% were considered
reliable and used for statistical analysis.
Clinical Data
Before TE examination, demographics, liver disease etiology
and anthropometric measurements were obtained. Biochemical
parameters including aspartate aminotransferase (AST), alanine
aminotransferase (ALT), platelet count, serum fasting glucose,
total cholesterol, and triglycerides were measured on the same day
as the LB.
Liver Biopsy
All patients underwent ultrasound-guided percutaneous LB.
The LB specimens were fixed in formalin and embedded in
paraffin. Then, 4-mm-thick sections were subjected to hematox-
ylin-eosin and Masson’s trichrome staining. All liver tissue samples
were evaluated by an experienced hepatopathologist (YN Park)
who had no access to the clinical data on the study population.
Liver fibrosis stage and necroinflammation were evaluated using
the Metavir or Brunt scoring system, according to the liver disease
etiology. [25,26] Steatosis was assessed as the percentage of
hepatocytes containing lipid droplets and categorized according to
the NAFLD Activity Score (S0, ,5%, S1, 5–33%; S2, 34–66%;
and S3, .66%). [27].
Statistical Analyses
Data are expressed as means6 SD, median (range), or n (%), as
appropriate. ‘Discordance’ was defined as a difference of at least
two steatosis stages between LB and CAP. Correlations between
variable were described using Spearman correlation coefficients
(r). Comparisons between patients with discordance and those
without were made using the Student t-tests or Mann-Whitney test
for continuous variables and chi-squared or Fisher’s exact test for
categorical variables. Cutoff CAP values to determine discordance
were calculated from our cohort, which maximized the sum of the
sensitivity (Se) and specificity (Sp) (Youden index). Positive and
negative predictive values (PPV and NPV) were also computed.
Areas under the receiver operating characteristic curves (AUROC)
were computed with 95% confidence intervals (CI). Univariate
and subsequent multivariate binary logistic regression analyses
were performed to identify independent factors of discordance
between LB and CAP. Odd ratios (ORs) and corresponding 95%
CI were also indicated. A P value ,0.05 on a two-tailed test was
considered significant. Data analyses were performed using the
SAS program (ver. 9.1; SAS Inc., Cary, NC, USA).
Results
Baseline Characteristics
During the study period, 170 patients with CLD (135 patients
who were recruited in our previous study [23] and additional 35
patients) were enrolled. However, after excluding 9 patients based
on our exclusion criteria, 161 patients were selected for statistical
analysis (Fig. 1). The baseline characteristics of the study are
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summarized in Table 1. The majority were male (n = 102, 63.4%)
and the median age was 49 years. The median body mass index
(BMI) was 24.4 kg/m2 and 28 (17.4%) patients had diabetes
mellitus. The main etiologies of CLD were NAFLD (n= 72,
44.7%), followed by chronic viral hepatitis including chronic
hepatitis B (n= 49, 30.4%) and C (n= 28, 17.4%), autoimmune
hepatitis (n = 8, 5.0%) and primary biliary cirrhosis (n = 4, 2.5%).
The median LS and CAP values were 8.1 (range, 2.9–75.0) kPa
and 255 (range, 149–400) dB/m, respectively. The median IQR/
M and IQR/MCAP were 0.12 (range, 0.01–0.35) and 0.12 (range,
0.02–0.33), respectively and IQR/M was higher than 0.3 in only
one patient.
Liver Histology and Corresponding CAP Value
The median length of the LB specimens was 18.5 (range, 16.1–
24.2) mm. The histological steatosis grade was S0 in 42 (26.1%)
patients, S1 in 80 (49.7%), S2 in 33 (20.5%), and S3 in 6 (3.7%),
respectively. The median CAP values for patients with S0, S1, S2,
and S3 steatosis on LB were 217 (range, 149–288), 258 (range,
150–345), 331 (range, 234–400), and 326 (range, 230–347) dB/m,
respectively. The median and range of CAP values according to
fibrosis stage and activity grade are listed in Table S1 in File S1.
CAP values were not significantly different between each fibrosis
stage and activity grade (all P.0.05).
The cutoff CAP values determining $S1, $S2, and S3 were
calculated as 250 dB/m (AUROC, 0.863 [95% CI, 0.807–0.920];
Se, 68.9%; Sp, 92.9%; PPV, 96.5%; NPV, 51.3%), 301 dB/m
(AUROC, 0.898 [95% CI, 0.841–0.954]; Se, 82.1%; Sp, 87.7%;
PPV, 68.1%; NPV, 93.9%), and 325 dB/m (AUROC, 0.738
[95% CI, 0.562–0.914]; Se, 50.3%; Sp, 81.3%; PPV, 9.4%; NPV,
97.7%), respectively.
Correlation between CAP and Clinicopathological
Variables
In univariate linear regression, CAP value was significantly
associated with BMI (P,0.001), ALT (P=0.003), total cholesterol
(P=0.002), IQR/MCAP (P,0.001), fibrosis stage (P=0.001),
activity grade (P,0.001), and steatosis grade (P,0.001). In
subsequent multiple linear regression analysis, CAP value was
independently associated with BMI (r=0.214, P=0.001) and
IQR/MCAP (r=20.216, P=0.001) along with histological
steatosis grade (r=0.455, P,0.001). (Table S2 in File S1).
Discordance between LB and CAP
Discordance between LB and CAP was observed in 13 (8.1%)
patients, whereas steatosis was underestimated on CAP in 5
(38.5%) patients and overestimated in 8 (61.5%) (Table 2). When
patients with and without discordance between LB and CAP were
compared, only the proportions of steatosis grade 3 and CAP
values were significantly higher in patients with discordance (all
P,0.05) (Table 3). Other clinical variables including distribution
of etiologies for CLD did not significantly differ between two
groups (Table 3).
Predictors of Discordance
In the first place, to identify independent risk factors for
discordance, we performed multivariate analysis using histological
parameters; the steatosis grade was entered into a multivariate
analysis along with other two variables (BMI and IQR/MCAP)
which showed an independent correlation with CAP value on
linear regression analysis. The histological activity grade was
entered simultaneously as a covariate into multivariate analysis to
adjust for the well-known overestimating influence of TE, given
that CAP is measured on the basis of TE. [22] Finally, on
multivariate analysis, only steatosis grade 3 was significantly
related to discordance (P=0.033; OR, 9.573; 95% CI, 1.207–
75.931) (Table 4). The percentages of discordance were
significantly higher in patients with steatosis grade 3 than in those
with steatosis grade 0–2 (2 of 6 [33.3%] vs. 11 of 155 [7.1%],
P=0.021) (Fig. 2).
Similarly, we performed multivariate analysis using clinical
parameters; CAP value was entered into multivariate analysis
along with two other variables (BMI and IQR/MCAP) which were
independently correlated with CAP value in linear regression
analysis. The ALT level, instead of the histological activity grade,
was entered simultaneously as a covariate into multivariate
analysis to adjust for the well-known overestimating influence of
TE, since CAP is measured on the basis of TE. [28,29] Finally, on
multivariate analysis, only CAP value was the only independent
predictor of discordance (P=0.006; OR, 1.020; 95% CI, 1.006–
1.034). The most discriminative CAP cutoff value to predict
discordance by maximizing the Youden index was 323 dB/m.
Patients with CAP.323 dB/m had a higher percentage of
discordance than those with CAP#323 dB/m. (8 of 33 [24.2%]
vs. 5 of 128 [3.9%], P=0.001) (Fig. 2).
Figure 1. Recruitment algorithm. A total of 170 patients with CLD were consecutively enrolled. However 9 patients were excluded due to TE
measurement failure (n = 3), unreliable LS measurement (n = 3), non-interpretable liver biopsies (n = 3), leaving 161 patients to be included in the
statistical analysis. CLD, chronic liver disease; TE, transient elastography; LS, liver stiffness.
doi:10.1371/journal.pone.0098689.g001
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Discussion
Although CAP showed promising results for non-invasive
diagnosis of the significant steatosis, it is not obvious whether
quantification of steatosis assessed by CAP could stratify severity of
steatosis accurately in patients with severe steatosis. [15–18] Myer
et al. reported that the diagnostic performance of CAP to identify
severe steatosis was sub-optimal [16], and the ability to differen-
tiate between steatosis grade 2 and 3 was not satisfactory in the
studies by Sasso et al. and Ledinghen et al. [15,17] Consistent with
these results, a high steatotic burden (steatosis grade 3 or high CAP
Table 1. Baseline characteristics (n = 161).
Variables Values
Demographic variables
Age (years) 49 (18–81)
Male gender 102 (63.4)
Body mass index (kg/m2) 24.4 (14.3–34.3)
Diabetes mellitus 28 (17.4)
Etiology, NAFLD/HBV/HCV/Others 72 (44.7)/49 (30.4)/28 (17.4)/12 (7.5)
Biochemical parameters
Aspartate aminotransferase (IU/L) 45.2636.2
Alanine aminotransferase (IU/L) 49.8643.8
Serum albumin (g/dL) 4.160.5
Fasting glucose (mg/mL) 109.6635.2




F0–1/F2/F3/F4 65 (40.4)/44 (27.3)/22 (13.7)/30 (18.6)
Activity grade
A0/A1/A2/A3 23 (14.3)/27 (16.8)/74 (46.0)/37 (23.0)
Steatosis
S0/S1/S2/S3 42 (26.1)/80 (49.7)/33 (20.5)/6 (3.7)
Biopsy length (cm) 18.5 (16.1–24.2)
Liver stiffness measurement
Liver stiffness value (kPa) 8.1 (2.9–75.0)
Interquartile range (kPa) 1.0 (0.1–14.0)
IQR/M 0.12 (0.01,0.35)
Controlled attenuation parameter
Controlled attenuation parameter value (dB/m) 255 (149–400)
Interquartile range (dB/m) 29.0 (6–76)
IQR/MCAP 0.12 (0.02–0.33)
Variables are expressed as median (range) or n (%). NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B; HCV, hepatitis C; kPa, kilopascal; IQR/M, interquartile range/
median liver stiffness value; CAP, controlled attenuation parameter; IQR/MCAP, interquartile range/median of CAP value.
doi:10.1371/journal.pone.0098689.t001
Table 2. Distribution of steatosis according to liver biopsy and CAP.
Steatosis according to liver biopsy Steatosis according to calculated cutoff CAP value
S0 (,250 dB/m, n=75) S1 ($250 dB/m, n=37) S2 ($301 dB/m, n=19) S3 ($325 dB/m, n=30)
S0 (n = 42) 39 3 0 0
S1 (n = 80) 32 31 9 8
S2 (n = 33) 3 2 9 19
S3 (n = 6) 1 1 1 3
CAP, controlled attenuation parameter.
Bold cells indicate the number of patients with discordance between LB and CAP values.
doi:10.1371/journal.pone.0098689.t002
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values) was selected as the independent risk factor of discordant
results between LB and CAP in our study.
To our knowledge, this is the first study to identify the factors
that influence the accuracy of CAP by using the end point of
discordance between LB and CAP values. Generally, it has been
known that LS values become more reliable when advanced
fibrosis or cirrhosis exists and that TE can diagnose liver cirrhosis
with higher accuracy. [21,30] In contrast, CAP was more accurate
in assessing less severe hepatic steatosis (#S2) in our study as well
as in those by Sasso et al. and Ledinghen et al., although LS and
CAP values were simultaneously measured from the same device.
[15,17] The reason for this opposite phenomenon of LS and CAP
is unclear. However, it can be hypothesized that the correlation
between ultrasonic attenuation and the amount of hepatic steatosis
may be diminished, especially when the steatosis is severe. Indeed,
steatosis grade 3 was selected as the only influencing factor in
discordance between LB and CAP. In addition, when only clinical
factors including CAP values were adjusted, only CAP values
independently influenced the discordance and its most discrimi-
native cutoff was similar to the cutoff value for diagnosing steatosis
grade 3 (323 vs. 325 dB/m). These results suggest that high CAP
values can be used as the single most significant factor in
determining the accuracy of CAP and thus, careful diagnosis
considering clinical correlations may be required when a patient
shows unexpectedly high CAP values. However, since a small
sample size of S3 with potential spectrum bias and interpretational
variability in grading histological hepatic steatosis may have
lowered the diagnostic performance of CAP in patients with high
steatotic burden, [31] further studies with a well-balanced
distribution of hepatic steatosis stages using objective assessment
tools such as computerized morphometry are required to clarify
the accuracy of CAP. [14,31].
A high ALT levels has been identified as one of the most
important confounders of LS values. [21] However, in the present
study, there was no significant correlation between ALT level and
CAP values, and ALT level was similar in patients with and
without discordance (mean 50.9 vs. 36.6 IU/L; P.0.05). Similar-
ly, histological necroinflammatory activity did not significantly





(n=13, 8.1%) P value
Demographic variables
Age (years) 49 (18–81) 52 (35–70) NS
Male gender 95 (64.2) 7 (53.8) NS
Body mass index (kg/m2) 24.4 (14.3–34.3) 24.5 (21.6–29.8) NS
Diabetes mellitus 23 (15.5) 5 (38.5) NS
Etiology, NAFLD/HBV/HCV/Others 64 (43.9)/45 (30.4)/26 (17.6)/12 (8.1) 7 (53.8)/4 (30.8)/2 (15.4)/0 (0.0) NS
Biochemical parameters
Aspartate aminotransferase (IU/L) 46.1637.1 34.5621.2 NS
Alanine aminotransferase (IU/L) 50.9645.0 36.6625.8 NS
Serum albumin (g/dL) 4.160.5 4.260.4 NS
Fasting glucose (mg/mL) 108.2634.6 124.0639.5 NS
Total cholesterol (mg/mL) 171.5640.9 180.1636.0 NS
Triglycerides (mg/mL) 126.2660.4 153.7654.9 NS
Liver biopsy
Fibrosis stage
F0–2/F3–4 99 (66.9)/49 (33.1) 10 (76.9)/3 (23.1) NS
Activity grade
A0–2/A3 114 (77.0)/34 (23.0) 9 (69.2)/4 (30.8) NS
Steatosis
S0–2/S3 144 (97.3 )/4 (2.7) 11 (84.6)/2 (15.4) 0.021
Biopsy length (cm) 18.2 (16.4–24.2) 18.6 (16.1–23.5) NS
Liver stiffness measurement
Liver stiffness value (kPa) 8.2 (2.9–75.0) 7.4 (3.0–17.5) NS
Interquartile range (kPa) 1.0 (0.1–14.0) 1.5 (0.4–2.6) NS
IQR/M 0.12 (0.01–0.35) 0.15 (0.06–0.26) NS
Controlled attenuation parameter
Controlled attenuation parameter value (dB/m) 250 (149–400) 327 (230–345) 0.010
Interquartile range (dB/m) 29.0 (6–72) 30.0 (15–76) NS
IQR/MCAP 0.12 (0.02–0.28) 0.10 (0.05–0.33) NS
Variables are expressed as median (range) or n (%).
NS, not significant; NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B; HCV, hepatitis C; kPa, kilopascal; IQR/M, interquartile range/median liver stiffness value;
CAP, controlled attenuation parameter; IQR/MCAP, interquartile range/median of CAP value.
doi:10.1371/journal.pone.0098689.t003
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influence discordance in our study, although previous studies
reported overestimation due to necroinflammation. [22] Although
there is still a chance that the influence of the high ALT level may
have been masked due to the relatively low mean ALT level
(49.8 IU/L) in our study population, our data suggest that the
influence of a high ALT level or necroinflammation on CAP
values seems negligible.
In our study, the effects of other clinical parameters on
discordance were also investigated. First, the influence of IQR/
MCAP on the accuracy of CAP was explored and assessed for use
as a surrogate marker for so called ‘‘reliable’’ criteria for CAP
value as IQR/M is currently used to determine the reliability of
LS value. [19] However, IQR/MCAP was not selected as an
independent predictor of discordance. In addition, we also tested
the influence of IQR/M on discordance, but it is not associated
with the diagnostic accuracy of CAP. Thus, it should be further
investigated whether IQR/MCAP or IQR/M can be incorporated
into ‘‘reliable’’ criteria for CAP, although IQR/M can influence
the accuracy of LS value. [19] Second, the influence of histological
necroinflammatory activity and ALT level were also tested, but
neither was associated with discordance, although previous studies
revealed that a higher activity grade or high ALT level can cause
significant overestimation of LS value. [22,32,33] These findings
suggest that CAP has different characteristics from LS measure-
ment and despite simultaneous measurement, should be interpret-
ed independently in terms of the accuracy of CAP and the
influence of necroinflammatory activity and ALT level. Lastly,
although we hypothesized that the BMI can be a surrogate marker
Figure 2. Percentage of patients with discordance according to histological steatosis grade and CAP value. The percentages of
discordance between liver biopsy and CAP were significantly higher in patients with steatosis grade 3 than in those with steatosis grade 0–2 (2 of 6
[33.3%] vs. 11 of 155 [7.1%], P=0.021). Additionally, patients with CAP.323 dB/m had a higher percentage of discordance than those with CAP#
323 dB/m. (8 of 33 [23.1%] vs.5 of 128 [4.9%], P= 0.001). CAP, controlled attenuation parameter.
doi:10.1371/journal.pone.0098689.g002
Table 4. Independent predictors of discordance between liver biopsy and CAP.
Variables P value Odd ratio (95% CI)
Model using histological parameters
Steatosis grade 3 0.033 9.573 (1.207–75.931)
Activity grade 3 NS –
*Body mass index (kg/m2) NS –
*IQR/MCAP NS –
Model using clinical parameters
CAP value (dB/m) 0.006 1.020 (1.006–1.034)
Alanine aminotransferase (IU/L) NS –
*Body mass index (kg/m2) NS –
*IQR/MCAP NS –
CAP, controlled attenuation parameters; CI, confidence interval; NS, not significant; IQR/MCAP, interquartile range/median of CAP value.
*Body mass index and IQR/MCAP were incorporated into multivariate analysis due to their significant correlations with CAP value in multivariate linear regression
analysis.
doi:10.1371/journal.pone.0098689.t004
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to predict the accuracy of CAP values considering a significant
association between BMI and CAP in our cohort, the BMI was not
correlated with the discordance. However, because the overall
BMI of our study population was not relatively high, the potential
influence of high BMI might have been masked. Thus, our results
did not clarify whether adjusting for BMI would increase the
accuracy of CAP interpretation; this should be investigated in
future.
Our study had several limitations. First, our cohort included
patients with CLDs due to various etiologies. As the diagnostic
performance could vary according to the etiology, the results may
have been influenced. However, other clinical variables including
steatosis grade and fibrosis stage did not significantly differ
according to etiologies. Additionally, recent studies demonstrated
that the accuracy of CAP was similar among different etiologies
including viral hepatitis and NAFLD, suggesting that heteroge-
neous etiologies may not have a major influence on our results.
[34] Second, the small sample size of severe steatosis and relatively
low mean BMI might also have led to a bias, which could be
related to the low diagnostic accuracy of CAP values for diagnosis
of S3 steatosis. Furthermore, the AUROC can vary according to
the prevalence of each steatosis grade. Thus, our results should be
confirmed in future studies with a good balance of sample size in
each steatosis grade and even BMI distribution. Third, the
relationship between metabolic syndrome and CAP could not be
fully evaluated in this study, as the assessment of metabolic
syndrome was feasible only in 60 of 161 (37.2%) patients.
Although, sub-group analysis revealed that metabolic syndrome
did not influence the risk of discordance between LB and CAP
(data not shown, P.0.05), further large scale study is required to
investigate the potential influence of metabolic syndrome on CAP.
Lastly, we defined our end point as ‘‘discordance of two steatosis
stages between LB and CAP’’. Although these analytical methods
have been used in several previous cross-sectional studies, [19,22]
this definition still seems to be obscure.
In conclusion, histological steatosis grade 3 and high CAP
values were identified as significant factors to decrease the
diagnostic performance of CAP. Thus, our results suggest that
high CAP values should be interpreted carefully and that
additional complementary diagnostic modality such as ultraso-
nography or serological steatosis prediction indices, should be used
to avoid errors in this area.
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